Mirek Baudys serves as the Scientific Director at Armata Pharmaceuticals, Inc., where he leverages over a decade of industrial experience to spearhead the formulation group dedicated to the development of proprietary antimicrobial polypeptides, known as STAMPs (Specifically Targeted AntiMicrobial Peptides). His extensive background in protein...
Mirek Baudys serves as the Scientific Director at Armata Pharmaceuticals, Inc., where he leverages over a decade of industrial experience to spearhead the formulation group dedicated to the development of proprietary antimicrobial polypeptides, known as STAMPs (Specifically Targeted AntiMicrobial Peptides). His extensive background in protein drug formulation, stabilization, and delivery is pivotal in advancing innovative therapeutic solutions aimed at combating antibiotic-resistant infections. Under his leadership, the formulation team focuses on optimizing the topical delivery of these novel peptides, ensuring their efficacy and safety through rigorous testing and characterization.
Mirek's expertise in protein purification and characterization, coupled with his proficiency in proteolytic enzymes, allows him to navigate complex challenges in drug development. His hands-on experience with advanced analytical techniques, including HPLC, UV/Vis spectroscopy, and ELISA, ensures that the formulations meet stringent regulatory standards set forth by the U.S. Food and Drug Administration (FDA). Additionally, his role encompasses technology transfer processes, where he collaborates with cross-functional teams to translate laboratory findings into scalable manufacturing practices.
Mirek's commitment to innovation in drug delivery systems is further exemplified by his involvement in clinical trials, particularly in phases I and II, where he applies his knowledge to enhance the therapeutic profiles of emerging products. His strategic vision and scientific acumen not only drive the success of Armata Pharmaceuticals but also contribute to the broader pharmaceutical landscape, addressing critical needs in antimicrobial therapy.
